Prospective Breast Cancer Biospecimen Collection
- Conditions
- Carcinoma in Situ of the BreastBreast CancerInvasive Breast Cancer
- Interventions
- Procedure: Tissue Sample collectionOther: Blood Sample CollectionOther: Rectal Swab
- Registration Number
- NCT04074720
- Lead Sponsor
- Thomas Jefferson University
- Brief Summary
Tissue will be procured during a standard of care procedure the patient will already be scheduled to undergo. A one time blood draw will be performed at this time and an optional rectal swab for biome analysis may occur. Follow Up will only consist of chart review to determine date of recurrence, metastases, and/or death
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
-
Adults >18 years old at time of consent
-
Subject must be capable to giving informed consent or have an acceptable surrogate capable of giving consent on the subject behalf.
-
Patients with carcinoma in situ or invasive breast cancer
-
Patient must be undergoing one of the following:
- definitive surgical tumor resection for breast cancer OR
- placement of a vascular access device as a prelude to neoadjuvant therapy for breast cancer OR
- neurosurgical resection of a brain metastasis from primary breast cancer.
- <18 years old
- Not able to give informed consent and does not have acceptable surrogate capable to giving informed consent.
- Active drug/alcohol dependence or abuse history
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Standard of Care Blood Sample Collection patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab Standard of Care Tissue Sample collection patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab Standard of Care Rectal Swab patients will have tissue procured after a standard of care procedure, a one time blood draw performed, and optional rectal swab
- Primary Outcome Measures
Name Time Method Tumor biomarker identification Up to 5 years Collected biospecimens will be analyzed using current laboratory techniques to identify the presence of breast cancer biomarkers such as estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2).
- Secondary Outcome Measures
Name Time Method Laboratory-based breast cancer tumor genomic profile Up to 5 years Genomic profile will be based on laboratory analysis of the collected tumor tissue biospecimens to identify how genes interact with the tumor and its environment.
Trial Locations
- Locations (1)
Sidney Kimmel Cancer Center at Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States